1. Home
  2. COGT vs CGBD Comparison

COGT vs CGBD Comparison

Compare COGT & CGBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COGT
  • CGBD
  • Stock Information
  • Founded
  • COGT 2014
  • CGBD 2012
  • Country
  • COGT United States
  • CGBD United States
  • Employees
  • COGT N/A
  • CGBD N/A
  • Industry
  • COGT Biotechnology: Pharmaceutical Preparations
  • CGBD Finance: Consumer Services
  • Sector
  • COGT Health Care
  • CGBD Finance
  • Exchange
  • COGT Nasdaq
  • CGBD Nasdaq
  • Market Cap
  • COGT 1.1B
  • CGBD 1.0B
  • IPO Year
  • COGT 2018
  • CGBD 2017
  • Fundamental
  • Price
  • COGT $11.70
  • CGBD $13.69
  • Analyst Decision
  • COGT Strong Buy
  • CGBD Hold
  • Analyst Count
  • COGT 9
  • CGBD 5
  • Target Price
  • COGT $20.25
  • CGBD $14.63
  • AVG Volume (30 Days)
  • COGT 1.8M
  • CGBD 493.0K
  • Earning Date
  • COGT 08-05-2025
  • CGBD 08-05-2025
  • Dividend Yield
  • COGT N/A
  • CGBD 12.45%
  • EPS Growth
  • COGT N/A
  • CGBD N/A
  • EPS
  • COGT N/A
  • CGBD 1.14
  • Revenue
  • COGT N/A
  • CGBD $234,464,000.00
  • Revenue This Year
  • COGT N/A
  • CGBD $14.27
  • Revenue Next Year
  • COGT N/A
  • CGBD $5.97
  • P/E Ratio
  • COGT N/A
  • CGBD $11.94
  • Revenue Growth
  • COGT N/A
  • CGBD N/A
  • 52 Week Low
  • COGT $3.72
  • CGBD $13.12
  • 52 Week High
  • COGT $12.97
  • CGBD $18.64
  • Technical
  • Relative Strength Index (RSI)
  • COGT 59.54
  • CGBD 44.58
  • Support Level
  • COGT $10.38
  • CGBD $13.69
  • Resistance Level
  • COGT $12.21
  • CGBD $13.85
  • Average True Range (ATR)
  • COGT 0.53
  • CGBD 0.27
  • MACD
  • COGT -0.16
  • CGBD -0.01
  • Stochastic Oscillator
  • COGT 64.13
  • CGBD 34.44

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

About CGBD Carlyle Secured Lending Inc.

Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.

Share on Social Networks: